Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
نویسندگان
چکیده
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clinicians should be aware of potential Aspergillus infections in patients treated with this drug.
منابع مشابه
Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review
Chronic lymphocytic leukemia is a lymphoproliferative disorder characterized by a gradual accumulation of neoplastic B-lymphocytes. Ibrutinib is a novel therapy for chronic lymphocytic leukemia. Ibrutinib therapy has been associated with nail plate abnormalities. Other common cutaneous adverse events caused by ibrutinib appear to be bruising, hair changes, pruritus, and rashes. We describe the ...
متن کاملIbrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.
Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.
متن کاملRash Associated with Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Ibrutinib is used in the treatment of chronic myeloid leukemia. While patients taking the drug have developed rashes, there are few case reports and studies documenting this adverse effect. We present a case of rash associated with Ibrutinib therapy in a patient with chronic lymphocytic leukemia.
متن کاملAn Unusual Case Report: Occurrence of Renal Cell Carcinoma, Basal Cell Carcinoma and Chronic Lymphocytic Leukemia in a Case of Papillary Thyroid Carcinoma Treated with Radioactive Iodine
The standard therapy for thyroid cancer is total or near total thyroidectomy, followed by the administration of radioactive iodine for remnant ablation or residual disease. Patients with radioiodine therapy are predisposed to second malignant neoplasms in organs such as central nervous system (CNS), breast, prostate, kidney, bone marrow, salivary gland, and digestive tract. Exposure to carcinog...
متن کاملThe HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Ibrutinib is an orally administered, covalent inhibitor of Bruton's tyrosine kinase with activity in B-cell malignancies based on Phase I/II studies. We describe the design and rationale for the Phase III HELIOS trial (trial registration: EudraCT No. 2012-000600-15; UTN No. U1111-1135-3745) investigating whether ibrutinib added to bendamustine and rituximab (BR) provides benefits over BR alone ...
متن کامل